Cargando…

Selectively Promiscuous Opioid Ligands: Discovery of High Affinity/Low Efficacy Opioid Ligands with Substantial Nociceptin Opioid Peptide Receptor Affinity

[Image: see text] Emerging clinical and preclinical evidence suggests that a compound displaying high affinity for μ, κ, and δ opioid (MOP, KOP, and DOP) receptors and antagonist activity at each, coupled with moderate affinity and efficacy at nociceptin opioid peptide (NOP) receptors will have util...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Vinod, Ridzwan, Irna E., Grivas, Konstantinos, Lewis, John W., Clark, Mary J., Meurice, Claire, Jimenez-Gomez, Corina, Pogozheva, Irina, Mosberg, Henry, Traynor, John R., Husbands, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033651/ https://www.ncbi.nlm.nih.gov/pubmed/24761755 http://dx.doi.org/10.1021/jm401964y

Ejemplares similares

Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands
por: Harland, Aubrie A., et al.
Publicado: (2016)

Discovery of the First Small-Molecule Opioid Pan Antagonist with Nanomolar Affinity at Mu, Delta, Kappa, and Nociceptin Opioid Receptors
por: Zaveri, Nurulain T., et al.
Publicado: (2015)

Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists
por: Park, Jong Yung, et al.
Publicado: (2019)

C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors
por: Cueva, Juan Pablo, et al.
Publicado: (2015)

Placement of Hydroxy Moiety on Pendant of Peptidomimetic Scaffold Modulates Mu and Kappa Opioid Receptor Efficacy
por: Harland, Aubrie A., et al.
Publicado: (2017)

Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships
por: Journigan, V. Blair, et al.
Publicado: (2017)

Bifunctional peptide-based opioid agonist/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain
por: Lagard, Camille, et al.
Publicado: (2016)

Nociceptin/orphanin FQ opioid receptor (NOP) selective ligand MCOPPB links anxiolytic and senolytic effects
por: Raffaele, Marco, et al.
Publicado: (2021)

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-administration through Nociceptin Opioid and Mu Opioid Receptors
por: Shen, Qianwei, et al.
Publicado: (2017)

Biased Opioid Ligands
por: Faouzi, Abdelfattah, et al.
Publicado: (2020)

Pharmacological profiles of opioid ligands at Kappa opioid receptors
por: Gharagozlou, Parham, et al.
Publicado: (2006)

Opioid Antagonists from the Orvinol Series as Potential Reversal Agents for Opioid Overdose
por: Disney, Alex, et al.
Publicado: (2022)

Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy
por: Olson, Keith M., et al.
Publicado: (2023)

Opioid-Modulated Receptor Localization and Erk1/2 Phosphorylation in Cells Coexpressing μ-Opioid and Nociceptin Receptors
por: Zhuo, Guan-Yu, et al.
Publicado: (2023)

Activity of opioid ligands in cells expressing cloned mu opioid receptors
por: Gharagozlou, Parham, et al.
Publicado: (2003)

Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity
por: Greedy, Benjamin M., et al.
Publicado: (2013)

Measuring ligand efficacy at the mu-opioid receptor using a conformational biosensor
por: Livingston, Kathryn E, et al.
Publicado: (2018)

Biased Opioid Ligands: Revolution or Evolution?
por: Noble, Florence, et al.
Publicado: (2021)

Activation profiles of opioid ligands in HEK cells expressing δ opioid receptors
por: Gharagozlou, Parham, et al.
Publicado: (2002)

Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family
por: Morse, Megan, et al.
Publicado: (2013)

Development of a Bioavailable μ Opioid Receptor (MOPr) Agonist, δ Opioid Receptor (DOPr) Antagonist Peptide That Evokes Antinociception without Development of Acute Tolerance
por: Mosberg, Henry I., et al.
Publicado: (2014)

Mechanistic Characterization of the Pharmacological Profile of HS-731, a Peripherally Acting Opioid Analgesic, at the µ-, δ-, κ-Opioid and Nociceptin Receptors
por: Puls, Kristina, et al.
Publicado: (2022)

Mutual Enhancement of Opioid and Adrenergic Receptors by Combinations of Opioids and Adrenergic Ligands Is Reflected in Molecular Complementarity of Ligands: Drug Development Possibilities
por: Root-Bernstein, Robert, et al.
Publicado: (2019)

Selective κ Opioid Antagonists nor-BNI, GNTI and JDTic Have Low Affinities for Non-Opioid Receptors and Transporters
por: Munro, Thomas A., et al.
Publicado: (2013)

Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible μ Opioid Receptor Antagonist Effects
por: Moynihan, Humphrey A., et al.
Publicado: (2012)

Development of a genetically-encoded sensor for probing endogenous nociceptin opioid peptide release
por: Zhou, Xuehan, et al.
Publicado: (2023)

Long‐term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox
por: Zamora, Joshua C., et al.
Publicado: (2021)

High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence
por: Wang, Hoau-Yan, et al.
Publicado: (2008)

Identification of novel ligands interacting with kappa opioid receptors
por: Spetea, Mariana, et al.
Publicado: (2011)

Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands
por: Sturaro, Chiara, et al.
Publicado: (2022)

Ligand and G-protein selectivity in the κ-opioid receptor
por: Han, Jianming, et al.
Publicado: (2023)

Ligand-Specific Regulation of the Endogenous Mu-Opioid Receptor by Chronic Treatment with Mu-Opioid Peptide Agonists
por: Murányi, Marianna, et al.
Publicado: (2013)

8-epi-Salvinorin B: crystal structure and affinity at the κ opioid receptor
por: Munro, Thomas A, et al.
Publicado: (2007)

Structure–Activity Relationships of 7-Substituted Dimethyltyrosine-Tetrahydroisoquinoline Opioid Peptidomimetics
por: Montgomery, Deanna, et al.
Publicado: (2019)

Retraction: High-Affinity Naloxone Binding to Filamin A Prevents Mu Opioid Receptor–Gs Coupling Underlying Opioid Tolerance and Dependence
Publicado: (2022)

Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?
por: Bailey, Sarah J., et al.
Publicado: (2018)

A ligand-based 3D pharmacophore model for the μ opioid receptor: application to the morphinan class of opioids
por: Asim, Muhammad Faheem, et al.
Publicado: (2010)

Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors
por: Mollica, Adriano, et al.
Publicado: (2017)

Promiscuous Ligands
por: McGovern, S.L.
Publicado: (2007)

Synthesis and Pharmacological Activities of 6-Glycine Substituted 14-Phenylpropoxymorphinans, a Novel Class of Opioids with High Opioid Receptor Affinities and Antinociceptive Potencies
por: Spetea, Mariana, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_fhbdg1lv7a0o6nmi0i0gpp6m5d